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Abstract 
Objective: 
Tourette’s syndrome is polygenic and highly heritable. Genome-wide association study (GWAS) approaches are 
useful for interrogating the genetic architecture and determinants of Tourette’s syndrome and other tic 
disorders. The authors conducted a GWAS meta-analysis and probed aggregated Tourette’s syndrome polygenic 
risk to test whether Tourette’s and related tic disorders have an underlying shared genetic etiology and whether 
Tourette’s polygenic risk scores correlate with worst-ever tic severity and may represent a potential predictor of 
disease severity. 
Methods: 
GWAS meta-analysis, gene-based association, and genetic enrichment analyses were conducted in 4,819 
Tourette’s syndrome case subjects and 9,488 control subjects. Replication of top loci was conducted in an 
independent population-based sample (706 case subjects, 6,068 control subjects). Relationships between 
Tourette’s polygenic risk scores (PRSs), other tic disorders, ascertainment, and tic severity were examined. 
Results: 
GWAS and gene-based analyses identified one genome-wide significant locus within FLT3 on chromosome 13, 
rs2504235, although this association was not replicated in the population-based sample. Genetic variants 
spanning evolutionarily conserved regions significantly explained 92.4% of Tourette’s syndrome heritability. 
Tourette’s-associated genes were significantly preferentially expressed in dorsolateral prefrontal cortex. 
Tourette’s PRS significantly predicted both Tourette’s syndrome and tic spectrum disorders status in the 
population-based sample. Tourette’s PRS also significantly correlated with worst-ever tic severity and was higher 
in case subjects with a family history of tics than in simplex case subjects. 
Conclusions: 
Modulation of gene expression through noncoding variants, particularly within cortico-striatal circuits, is 
implicated as a fundamental mechanism in Tourette’s syndrome pathogenesis. At a genetic level, tic disorders 
represent a continuous spectrum of disease, supporting the unification of Tourette’s syndrome and other tic 
disorders in future diagnostic schemata. Tourette’s PRSs derived from sufficiently large samples may be useful in 
the future for predicting conversion of transient tics to chronic tic disorders, as well as tic persistence and 
lifetime tic severity. 
 
Tourette’s syndrome is a complex neuropsychiatric disorder that occurs along a phenotypic spectrum that also 
includes chronic (persistent) motor or vocal tic disorder (chronic tics) and transient (provisional) tic disorder (1). 
Although Tourette’s syndrome is highly heritable (2), variants in known Tourette’s risk genes 
(e.g., CNTN6, NRXN1, SLITRK1, HDC, and CELSR3) account for less than 2% of affected individuals (3–6). 
Tourette’s syndrome is highly polygenic, with a demonstrated role for multiple common genetic variants of 
small effect distributed widely across the genome (7). Thus, genome-wide association studies (GWASs) (8) will 
be of benefit in further elucidating the underlying genetic etiology of the disorder. 
To date, only one Tourette’s GWAS has been published (9). Although no single-nucleotide polymorphisms (SNPs) 
met criteria for genome-wide significance (p<5×10−8), in aggregate, the top SNPs (p values <1×10−3) were 
enriched for expression quantitative trait loci (eQTLs) in the frontal cortex and for methylation quantitative trait 
loci (mQTLs) in the cerebellum, indicating that a significant proportion of these variants have biological 
relevance to Tourette’s syndrome, and perhaps also to other tic disorders. However, as with other 
neuropsychiatric disorders, much larger sample sizes are needed to elucidate the disorder’s genetic 
underpinnings. Here, we report the results of a GWAS meta-analysis from the Psychiatric Genomics Consortium 
(PGC) Tourette Syndrome Workgroup in a sample that is nearly four times larger than the initial GWAS (9). We 
also probed aggregated Tourette’s syndrome polygenic risk to test two specific hypotheses: whether Tourette’s 
and related tic disorders have an underlying shared genetic etiology and whether Tourette’s polygenic risk 
scores correlate with worst-ever tic severity and may represent a future potential predictor of disease severity. 
Methods 
Study Subjects 
The primary GWAS meta-analysis consisted of four European ancestry (EU) GWAS data sets: 1) 969 case subjects 
and 3,923 ancestry-matched control subjects from the initial Tourette’s syndrome GWAS (GWAS1) (9); 2) 2,711 
additional EU Tourette’s case subjects (4) and 3,762 ancestry-matched control subjects (GWAS2); 3) Tourette’s 
probands from GWAS1 and one or more of their Tourette’s-affected family members (10) (N=548) plus 597 
ancestry-matched control subjects (GWAS2 FAM); and 4) 591 independent EU Tourette’s probands from the 
Tourette International Collaborative Genetics (TIC) study (11) and 1,206 unselected ancestry-matched control 
subjects. Genotyping details are provided in Tables S1 and S2 in the online supplement. 
GWAS1. 
A total of 1,285 EU case subjects (number of cases from the GWAS1 paper) were collected from Tourette’s 
syndrome specialty clinics in the United States, Canada, the United Kingdom, and the Netherlands or through 
recruitment from the membership of the Tourette Association of America. Tourette’s diagnoses were based on 
DSM-IV-TR criteria plus observation of tics by an experienced clinician. After removing the subjects who were 
relatives or duplicates of subjects in GWAS2 or GWAS2 FAM, a total of 969 cases were retained for analysis. A 
total of 3,923 control subjects were identified primarily from previously genotyped unselected population 
control subjects and were ancestry-matched to the case subjects (9). 
GWAS2. 
A total of 2,871 EU case subjects with DSM-5 Tourette’s syndrome were identified by e-mail or online 
recruitment combined with validated, web-based phenotypic assessments (12, 13) (N=1,264) or from Tourette’s 
syndrome specialty clinics in the United States, Canada, and Europe (N=1,607) (see the Supplemental Methods 
section in the online supplement). All subjects were genotyped at the UCLA Neuroscience Genomics Core. After 
quality control, 2,711 case subjects were retained for analysis. 
GWAS2 FAM. 
The family sample consisted of 548 probands and first-degree relatives with Tourette’s syndrome from 207 
independent families (10). A total of 175 probands came from the original Tourette’s GWAS1 sample; these case 
subjects were removed from the GWAS1 analysis along with ancestry-matched control subjects and reanalyzed 
with the family-based sample. Thirty-two Tourette’s probands and 341 additional Tourette’s-affected family 
members (total N=373) were genotyped along with the GWAS2 case-control sample. A total of 597 ancestry-
matched control subjects were selected from a pool of previously genotyped control subjects (see the 
Supplemental Methods section in the online supplement). 
TIC. 
The TIC Genetics sample consisted of 591 probands, 579 of whom met DSM-5 criteria for Tourette’s syndrome 
and 12 of whom met criteria for DSM-5 chronic motor or vocal tic disorder (see Tables S1 and S2 in the online 
supplement). 
Control subjects. 
A total of 6,920 EU control subjects were obtained from cohorts of previously genotyped unselected population 
control subjects for the GWAS2, GWAS2 FAM, and TIC Genetics analyses; an additional 595 EU control subjects 
were genotyped with the Tourette’s case subjects at the UCLA Neuroscience Genomics Core (see Table S1 and 
the Supplemental Methods section in the online supplement). 
deCODE. 
An independent case-control replication sample from Iceland (deCODE genetics, Reykjavik) consisted of 706 
Icelandic Tourette’s syndrome case subjects and 466 case subjects with other tic disorders (chronic tics or 
unspecified tic disorder) (see the Supplemental Methods section in the online supplement). A total of 127,164 
unscreened population-matched control subjects were also available, of whom 6,068 were screened and 
reported no lifetime subclinical motor or vocal tics. Case and control subjects were genotyped at deCODE on 
Illumina SNP arrays (see the Supplemental Methods section). 
Participants age 18 and older provided written informed consent; individuals under 18 gave assent, and parental 
permission was obtained. The study was approved by the human subjects committees at all participating sites. 
Quality Control 
Genotyping quality control was performed in PLINK, version 1.9 (14) (see the Supplemental Methods section). 
Duplicates and relatives were identified using genome-wide identity-by-descent estimates, and one member of 
each duplicate or relative pair was removed from the case-control sample. Relative pairs in which both 
individuals had a Tourette’s diagnosis were removed from the case-control sample and moved to the family-
based analysis. 
Population stratification was assessed through multidimensional scaling (MDS) analysis; individuals of non-
European ancestry and extreme outliers on each of the MDS components were removed (see the Supplemental 
Methods section and Figure S1 in the online supplement). Case-control matching was verified across all MDS 
components. The final post–quality control GWAS2 sample contained 2,711 case subjects, 3,762 ancestry-
matched control subjects, and 550,550 SNPs; the final GWAS2 FAM sample contained 548 case subjects and 
family members, 597 ancestry-matched control subjects, and 236,748 SNPs. The final TIC sample included 591 
case subjects, 1,206 ancestry-matched control subjects, and 581,774 SNPs (see Table S2 in the online 
supplement). 
Imputation and Genome-Wide Association 
SNP imputation was conducted on all genotype data for the primary meta-analyses using the 1000 Genomes 
Project phase 1 integrated haplotypes (December 2013 release, with singleton sites removed) as the reference 
panel (15). SHAPEIT was used to phase genotype data, followed by imputation with IMPUTE, version 2. SNPs 
with INFO score <0.6 or certainty <0.9 were excluded. 
Genome-wide association tests were performed on the imputed dosage data of the GWAS2 and TIC samples 
separately in PLINK 1.9, using logistic regression under an additive model with the first four MDS components 
and any additional MDS components associated with Tourette’s case-control status at p<0.05 included as 
covariates. A linear mixed model was used for the GWAS2 FAM association analysis in MMM, version 1.0 (16), to 
control for familial relatedness. GWAS1 samples were reimputed as described above; association tests were 
performed in four ancestry-based strata: nonisolate European (GWAS1_EU), Ashkenazi Jewish (GWAS1_AJ), 
French Canadian (GWAS1_FC), and GWAS1 TIC (GWAS1_TIC) (see Table S2). 
A primary GWAS meta-analysis was conducted on the GWAS1, GWAS2, GWAS2 FAM, and TIC data sets using the 
inverse-variance method in METAL (17). Heterogeneity was assessed with Cochran’s I2 statistic. The genomic 
control factor (λ) was calculated for each individual GWAS and for the overall meta-analysis using all SNPs with 
minor allele frequency (MAF) >0.01 to identify residual population stratification or systematic technical artifact 
(see Figure S2 in the online supplement). GWAS summary statistics were subjected to linkage disequilibrium (LD) 
score regression (LDSC) analyses on high-quality common SNPs (INFO score >0.9 and MAF >0.01) to examine the 
LDSC intercept as a more specific measure of inflation of the GWAS test statistic (18) due to residual artifact or 
stratification. The genome-wide significance threshold for the GWAS (19, 20) was set at a p value of 5.0×10−8. 
Heritability Estimation 
Tourette’s syndrome SNP-based heritability was estimated on the liability scale, assuming a population 
prevalence of 0.8% (21), using both LDSC (18) and, in the GWAS1 and GWAS2 samples after excluding Ashkenazi 
Jewish and French Canadian samples, genotype-level data in a linear mixed model framework (7). To compare 
the relative polygenic burden of Tourette’s samples collected with different ascertainment methods, the 
Tourette’s GWAS1 and GWAS2 data sets were separated into three groups: GWAS1 case subjects (25% from 
affected sibling-pair families) (10); GWAS2 case subjects recruited through Tourette’s syndrome specialty clinics; 
and GWAS2 case subjects recruited via e-mail from the membership of the Tourette Association of America and 
assessed with a web-based phenotyping instrument (12). After additional stringent quality control of SNPs and 
samples (see the Supplemental Methods section), the SNP-based heritability of each ascertainment group was 
estimated both separately and jointly. 
Partitioned heritability analyses were conducted using LDSC to evaluate enrichment of Tourette’s SNP-based 
heritability from different functional annotation classes and different cell or tissue types (22) and to examine 
genetic correlations between the GWAS1, GWAS2, and TIC data sets. 
Targeted Replication 
The population-based deCODE samples were used 1) to independently replicate the 39 top LD-independent 
SNPs (r2<0.2 and MAF>0.01; p<1.0×10−5) in the primary meta-analysis, followed by a sign test to examine 
consistency in the direction of effects in these top SNPs across the two data sets, as well as a targeted meta-
analysis of these 39 SNPs using the inverse-variance method (see the Supplemental Methods section); and 2) to 
examine the genetic relationships between Tourette’s and other tic disorders through polygenic risk score (PRS) 
analyses (see the Supplemental Methods section) (23). Logistic regressions were performed to test the 
prediction power of PRS for Tourette’s syndrome and tic disorder case subjects compared with control subjects, 
adjusted by sex, year of birth, and the first 20 principal components (24). 
Polygenic Risk Score Analyses 
Genome-wide Tourette’s PRSs adjusted for ancestry principal components (aPRSs) were generated for all 
subjects in the primary meta-analysis using the entire distribution (GWAS p≤1) of LD-independent SNPs (r2<0.2) 
through a cross-validation approach (23) and used to examine the relationship between Tourette’s aPRS and 
ascertainment, family history of Tourette’s or chronic tics, and lifetime worst-ever tic severity (Yale Global Tic 
Severity Scale total tic score [tic severity], range 0–50) (see the Supplemental Methods section). 
Gene-Based and Gene Set Enrichment Analysis 
Gene-based tests and competitive gene set enrichment analyses were conducted in MAGMA (25) (see the 
Supplemental Methods section). Gene-based test statistics were derived using association summary statistics for 
all SNPs assigned to each gene including 50-kb flanking regions after accounting for LD, and p values were 
adjusted with a Bonferroni correction for 18,079 genes genome-wide. Gene-based statistics were then analyzed 
for tissue expression enrichment in 53 distinct human tissues from 714 donors using GTEx RNA-seq data (26), 
and Bonferroni correction was applied for 53 tissue types (p=0.05/53=9.4×10−4). Tested gene sets included 107 
probable autism spectrum disorder susceptibility genes from exome sequencing studies (27), evolutionarily 
constrained genes (probability of loss-of-function intolerance score >0.9), previously identified constrained 
genes harboring deleterious rare variants (large copy number variants or de novo loss-of-function mutations) in 
Tourette’s case subjects (4, 5), and all Gene Ontology terms from the Molecular Signatures Database, version 6.0 
(MSigDB 6.0) (see the Supplemental Methods section). Bonferroni correction was applied for the number of 
gene sets tested. 
Results 
Genome-Wide Association Study 
The final GWAS meta-analysis consisted of 8,265,319 SNPs in 4,819 Tourette’s syndrome case subjects and 9,488 
control subjects. No evidence of residual population stratification or systematic technical artifact was observed 
in any of the individual data sets (see Figure S2 in the online supplement) or in the final meta-analysis (λ=1.072, 
λ1000=1.011) (Figure 1). LDSC indicated that 86% of the observed test statistic inflation was attributable to an 
underlying genome-wide polygenic signal (see Figure S3 in the online supplement). PRS analyses in each 
individual GWAS data set, derived using a leave-one-out approach, as well as in the deCODE sample, indicated 
genetic homogeneity across all contributing data sets (see Figures S4 and S5 in the online supplement). 
 
FIGURE 1. Results of the primary Tourette’s syndrome genome-wide association study meta-analysis of 4,819 
case subjects and 9,488 control subjectsa 
a Panel A is a quantile-quantile plot of observed versus expected −log10(p) values from the primary genome-wide 
association study (GWAS) meta-analysis. The 95% confidence interval of expected values is indicated in gray. The 
genomic control λ value is 1.072, and the λ1000 value is 1.011 for single-nucleotide polymorphisms (SNPs) with 
minor allele frequency >0.01, INFO score (measurement of imputation quality) >0.6, and certainty >0.9. Panel B 
is a Manhattan plot of all final genotyped and imputed SNPs in the primary Tourette’s syndrome GWAS meta-
analysis. The upper horizontal line indicates the genome-wide significance threshold of 5×10−8, and the lower 
horizontal line indicates the suggestive threshold of 1.0×10−5. 
The top SNP in the GWAS meta-analysis, rs2504235, located on chromosome 13q12.2, surpassed the genome-
wide significance threshold (odds ratio=1.16, p=2.1×10−8) (Table 1; see also Figure S6 in the online supplement). 
rs2504235 lies within an intron of FLT3, encoding FMS-like tyrosine kinase 3. No other SNPs achieved genome-
wide significance, although rs1933437, a common FLT3 missense variant (Thr227Met) that lies 11.4 kb away 
from and is in strong LD with rs2504235 (r2=0.93), had a p value of 8.2×10−8 (see Table S3 in the online 
supplement). Across the genome, 39 LD-independent index SNPs with p values <1×10−5 were identified by LD 
pruning (r2<0.2) followed by conditional association analyses controlling for the most significant SNP within each 
2-Mb window and manual inspection of regional association plots to confirm the presence of supporting 
statistical evidence of association from nearby SNPs (see Tables S3 and S4 in the online supplement). The top 10 
LD-independent index SNPs are presented in Table 1. 
TABLE 1. Top 10 linkage disequilibrium–independent loci in the primary Tourette’s syndrome GWAS meta-
analysisa 
    Primary Meta-Analysis    
SNP CHR BP A1/A2 INFO Score MAF Odds Ratio p 
rs2504235 13 28,612,886 A/G 0.99 0.38 1.16 2.1E–08 
rs191044310 10 23,705,451 A/T 0.83 0.02 0.54 1.5E–07 
rs13407215 2 161,544,891 T/C 1.00 0.02 2.21 1.9E–07 
rs2708146 2 58955953 G/A 1.009 0.46 0.88 3.2E–07 
rs1906252b 6 98,550,289 A/C 1.00 0.49 0.88 7.0E–07 
rs12459560 19 52,318,380 T/G 0.98 0.15 1.19 8.2E–07 
rs117648881 8 113,581,898 A/G 0.77 0.02 0.59 8.8E–07 
rs6670211 1 29,576,784 A/C 1.00 0.47 0.88 1.4E–06 
rs72853320 6 36,623,338 A/G 1.00 0.13 1.20 1.7E–06 
rs73205493 4 2,460,571 T/C 0.89 0.34 1.16 1.8E–06 
a For each linkage disequilibrium (LD) independent locus, the minor allele frequency (MAF), odds ratio, and association p 
value of the index single-nucleotide polymorphism (SNP) is presented for the primary Tourette’s syndrome GWAS meta-
analysis of 4,819 Tourette’s case subjects and 9,488 control subjects, for the targeted replication in the independent 
deCODE sample (706 Tourette’s case subjects and 6,068 control subjects), and for the meta-analysis of these two data sets. 
Complete annotation of these SNPs and all SNPs with association p values ,1.0310–5 is provided in Tables S3 and S4 in the 
online supplement. CHR=chromosome; BP=hg19 position; A1=minor allele; A2=major allele; INFO score=measurement of 
imputation quality; LD block=chromosomal regions where SNPs are in linkage disequilibrium with the index SNP (r2 .0.2) 
with association p value,0.05. b rs1906252 and the LD block defined by r2.0.2 were reported to be associated with other 
disorders and measures, including bipolar disorder, educational attainment, gut microbiota, and intelligence. 
 
Targeted Replication 
The 39 LD-independent index SNPs with p<1×10−5 were investigated for replication in the deCODE sample (706 
case subjects, 6,068 control subjects). None of the individual SNPs were replicated after Bonferroni correction 
(replication threshold for 39 tests, p<0.0013) (see Table 1; see also Table S4 in the online supplement); 23 of 39 
putative Tourette’s syndrome risk alleles had the same direction of effect, although this was not statistically 
significant (binomial two-way sign test, p=0.34). 
Meta-analysis restricted to these 39 SNPs was conducted using summary statistics from the primary meta-
analysis and the deCODE data with the inverse variance method in METAL. No SNP achieved genome-wide 
significance; the SNP with the lowest p value was rs13407215, on chromosome 2 (p=1.9×10−7). rs2504235 was 
not genome-wide significant in this analysis (p=2.4×10−7) (see Table 1; see also Table S4). 
Heritability and PRS Analyses 
Tourette’s syndrome SNP-based heritability (h2g) was estimated in the primary GWAS meta-analysis using LDSC 
(h2g=0.21, SE=0.024, p<2.0×10−16). Pairwise genetic correlations across the three independent case-control data 
sets (GWAS1, GWAS2, TIC) confirmed a significant shared polygenic architecture (GWAS1-GWAS2: rg=0.86, 
SE=0.21, p=3.9×10−5; GWAS1-TIC: rg=0.84, SE=0.30, p=4.5×10−3; GWAS2-TIC: rg=0.93, SE=0.26, p=4×10−4). 
Because the previous estimate of Tourette’s syndrome h2g from the first Tourette’s GWAS (linear mixed model, 
h2g=0.58, SE=0.09) (7) was significantly higher than that observed in this study, additional heritability analyses 
were conducted in the individual data sets, stratified on ascertainment status, using linear mixed models (LMM) 
(7) (Table 2). These analyses confirmed both the high SNP-based heritability of the sibling-pair-enriched 
Tourette’s GWAS1 sample (GWAS1-LMM: h2g=0.56, SE=0.10; p=1.2×10−9) and the lower heritability of the larger 
GWAS2 sample (GWAS2-LMM: h2g=0.29, SE=0.04; p=5.5×10−14). 
TABLE 2. Single-nucleotide polymorphism–based heritability estimates derived using a linear 
mixed model method for the Tourette’s syndrome GWAS1 and GWAS2 European ancestry case-control samplesa 
 Case Subjects  Control Subjects     
Sample N % N % V(G)/Vp_Lb SE p 
GWAS1 559 14 3,400 86 0.565 0.096 1.2310–9 
GWAS2c 2,146 46 2,564 54 0.288 0.040 5.5310–14 
GWAS2c web-based 934 27 2,564 73 0.294 0.067 2.4310–6 
GWAS2c clinic-based 1,098 30 2,564 70 0.284 0.059 4.0310–7 
a Heritability estimates were calculated first for the entire Tourette’s syndrome GWAS1 and GWAS2 samples; subsequently, 
the Tourette’s GWAS2 sample was separated into two subsets based on case ascertainment method (clinic-based versus 
web-based). The TIC Genetics case-control sample was not large enough to obtain an independent heritability estimate 
using a linear mixedmodel approach. All heritability estimates are presented on the liability scale. Subjects from European 
population isolates (Ashkenazi Jewish and French Canadian)were excluded from the linear mixed-model analyses. 
b Tourette’s syndrome prevalence was defined as 0.8%. 
c GWAS2 family data were not included in the heritability estimate. 
 
To explore the hypothesis that the lower heritability of the Tourette’s GWAS2 sample may have arisen from the 
inclusion of Tourette’s case subjects diagnosed in the community and ascertained using a validated web-based 
screen (12, 13), the GWAS2 case-control sample was divided into clinic-based and web-based case subjects, and 
the LMM-based heritability analyses were repeated. Contrary to the predicted hypothesis, both subsets had the 
same heritability (GWAS2-clinic: h2g=0.29, SE=0.07; p=1.2×10−9; GWAS2-web: h2g=0.28, SE=0.10; p=1.2×10−9) 
(see Table 2). 
Tourette’s Syndrome PRS in Multiplex Versus Simplex Families 
Since a large proportion of Tourette’s GWAS1 case subjects were derived from affected sibling-pair families, 
which might be expected to harbor higher Tourette’s syndrome polygenic risk than case subjects from simplex 
families without affected first-degree relatives, we examined the relationship between ancestry-adjusted PRS 
(aPRS) in case subjects from multiplex families (positive for first-degree relative family history) compared with 
simplex families (negative for first-degree relative family history) (see the Supplemental Methods section). 
Because multiplex Tourette’s syndrome case subjects with a Tourette’s-affected parent or sibling (N=417) 
demonstrated mean aPRSs similar to Tourette’s GWAS case subjects with a chronic tic-affected parent or sibling 
(N=111) (F=0.12, df=1, p=0.73), we combined both Tourette’s case groups for further analyses 
(Tourette’s/chronic tic family history positive case subjects, N=528). The combined Tourette’s/chronic tic 
multiplex case subjects had a significantly higher mean aPRS compared with the aPRS from Tourette’s/chronic 
tic simplex case subjects (N=346) (F=4.90, df=1, p=0.027), confirming that multiplex case subjects were enriched 
for Tourette’s polygenic risk (see Figure S7 in the online supplement). 
Tourette’s Syndrome PRS and Tic Severity 
Given the strong enrichment of Tourette’s aPRS in case subjects from multiplex families, Tourette’s/chronic tic 
family history positive Tourette’s case subjects were examined next to test whether Tourette’s aPRS may serve 
as a predictor of higher disease severity in these case subjects (see the Supplemental Methods section). After 
adjustment for residual population stratification using the first four principal components, higher Tourette’s 
aPRS was significantly correlated with increased worst-ever tic severity (β=0.93, SE=0.42, p=0.026), with every 
one-standard-deviation increase in Tourette’s aPRS corresponding to a 0.93-point increase in worst-ever tic 
severity (total range, 0–50). 
Tourette’s Syndrome and Tic Spectrum Phenotypes 
Given the hypothesis that Tourette’s and other tic disorders represent a phenotypic spectrum with a shared 
genetic etiology, Tourette’s PRS derived from the GWAS meta-analysis was compared in Tourette’s and tic 
spectrum case subjects in the Icelandic deCODE sample (Figure 2; see also Figure S5 in the online supplement). 
Tourette’s PRS was significantly higher in both deCODE Tourette’s case subjects and tic spectrum case subjects 
compared with control subjects (odds ratio=1.33, p=5.3×10−9, and odds ratio=1.20, p=5.2×10−4, respectively), 
explaining 0.78% and 0.42% of the phenotypic variance, respectively. Direct comparison between case groups 
confirmed that deCODE Tourette’s case subjects carried a higher Tourette’s syndrome polygenic burden than 
subjects with other tic spectrum disorders (odds ratio=1.14, p=0.05), representing an excess 0.37% of the 
phenotypic variance (see Figure 2). 
 
FIGURE 2. Density plot demonstrating the distribution of Tourette’s syndrome polygenic risk scores (PRSs) in 
population-based Icelandic Tourette’s case subjects, tic disorder case subjects, unscreened population control 
subjects, and tic-negative control subjectsa 
a The x-axis represents the scaled Tourette’s syndrome PRS score, where an increase of one standard deviation 
in PRS score doubles Tourette’s syndrome risk. The dashed lines correspond to the mean of the respective 
groups. The black dotted line toward the right corresponds to one standard deviation from the population 
mean. 
Enrichment of Tourette’s Syndrome Heritability by Functional Annotation and Gene 
Expression 
Tourette’s syndrome SNP-based heritability (h2g) from the GWAS meta-analysis was also used as a genome-wide 
probe to test whether aggregated Tourette’s syndrome genetic risk may be concentrated either in 52 specific 
functional genomic elements (e.g., promoters, enhancers, epigenetic marks) or in gene expression patterns from 
10 grouped tissue or cell types using partitioned LDSC (22). Evolutionarily conserved SNPs (2.6% of all SNPs) 
were enriched 16.5-fold for Tourette’s h2g, accounting for 42.3% of Tourette’s syndrome heritability 
(Pr[h2g]/Pr[SNPs]=16.5, SE=5.3, p=3.6×10−3, not significant after correction). A parallel analysis including these 
evolutionarily conserved SNPs plus 500-bp flanking windows (33% of all SNPs) was enriched 2.8-fold for 
Tourette’s h2g and accounted for 92.4% of Tourette’s syndrome heritability (Pr[h2g]/Pr[SNPs]=2.80, SE=0.46, 
p=1.0×10−4; p=0.005 after correction) (see Figure S8 in the online supplement). No other genomic annotations 
were significantly enriched for Tourette’s SNP-based heritability. In the cell-type analysis, significant enrichment 
was found only for CNS cell types, with 62.7% of Tourette’s syndrome heritability contributed by 14.8% of SNPs 
(p=4.2×10−8; p=4.2×10−7 after correction) (see Figure S9 in the online supplement). 
Gene-Based Association and Enrichment Analyses 
Gene-based association and enrichment tests were performed using meta-analysis summary statistics in 
MAGMA and gene expression data in GTEx (https://www.gtexportal.org/home/). FLT3 was identified with 
genome-wide significant association after correcting for 18,079 gene tests (p=8.9×10−7) (see Figure S10 in 
the online supplement). The most significant SNP in the FLT3 locus, rs2504235, was the only SNP surpassing 
genome-wide significance threshold in the primary meta-analysis and was significantly associated 
with FLT3 expression level both in cerebellum (p=6.5×10−10) and cerebral cortex (p=2.6×10−11). No gene set was 
significantly associated with Tourette’s syndrome after Bonferroni correction. In the gene expression 
enrichment analyses of 53 adult human tissues, only dorsolateral prefrontal cortex (Brodmann’s area 9) 
demonstrated significant enrichment of Tourette’s-associated genes after correction (β=0.023, SE=0.0069, 
p=1.2×10−4) (Figure 3; see also the Supplemental Methods section). 
 
FIGURE 3. Gene expression enrichment analysis of genome-wide Tourette’s syndrome polygenic risk in 53 adult 
human tissuesa 
a Gene-based test statistics were derived from Tourette’s syndrome GWAS meta-analysis summary statistics on 
single-nucleotide polymorphisms (SNPs) with minor allele frequency >0.01 and INFO score (measurement of 
imputation quality) >0.9. SNPs were assigned to genes based on their position according to NCBI Build 37.3 and 
50-kb upstream and downstream flanking regions. Summary statistics on 18,079 genes were generated. The 
European panel of the 1000 Genomes data (phase 3) was used as the reference panel to account for linkage 
disequilibrium. GTEx (version 7) RNA-seq data expression values were log2 transformed with a pseudo-count of 
1 after Winsorization at 50, and the average was taken per tissue. Fifty-three specific tissue types were tested 
separately in MAGMA (23). The significance threshold for the tissue-specific test was calculated using the 
Bonferroni method (alpha=0.05/53, p<9.43×10−4). Frontal cortex (Brodmann’s area [BA] 9), corresponding to 
dorsolateral prefrontal cortex, demonstrated significant enrichment of Tourette’s-related genes after correction 
for multiple hypothesis testing. 
Discussion 
Tourette’s syndrome has long been conceptualized as part of a spectrum of developmental tic disorders, with 
transient tics at one end (1) and severe Tourette’s syndrome with multiple psychiatric comorbidities at the 
other. However, until recently, potential biological relationships between the various tic disorders were 
unknown, as were the underlying genetic contributions to tic severity. The results of this study further illuminate 
the genetic architecture of Tourette’s syndrome and its relationships to phenotypic expression. First, the PRS 
analyses probing the genetic architecture of tic disorders in the population-based Icelandic sample demonstrate 
that individuals with Tourette’s syndrome share the same underlying polygenic risk as those with other tic 
disorders. Furthermore, the observation that Tourette’s syndrome case subjects have a significantly higher 
mean PRS than those with non-Tourette’s tic disorders provides evidence for a liability spectrum of genetic risk 
within tic disorders. Lastly, within Tourette’s syndrome case subjects, the finding that higher Tourette’s PRS was 
associated with greater tic severity also builds on our previous analyses demonstrating a relationship between 
higher Tourette’s PRS and the presence of complex symmetry and socially inappropriate tics (28). These 
relationships, although hypothesized on the basis of clinical observations, have not previously been 
demonstrated at the molecular genetic level, and ultimately they will help provide insight into the molecular 
mechanisms of tic development and expression. 
These observations have direct biological and clinical relevance. First, they support previous efforts to 
conceptualize Tourette’s and chronic tics as a unified condition and to combine them into a single tic spectrum 
disorder in future diagnostic schemas (1). Although traditionally separated clinically into distinct disorders, 
chronic/persistent tic disorders, whether consisting of motor tics, vocal tics, or both, appear to be due to the 
same underlying genetic causes. Second, while the small proportion of explained variance in worst-ever tic 
severity is a limitation of the present study, work in other polygenic psychiatric disorders, such as schizophrenia, 
has repeatedly demonstrated that as GWAS sample sizes increase, the proportion of phenotype explained by 
polygenic risk scores increases markedly (29). It is therefore possible that in the future, Tourette’s PRS may be a 
potential candidate for predicting both conversion to chronic tics in the 20%−25% of children who present with 
transient tics (1) and, at the other end of the phenotypic spectrum, tic persistence and lifetime tic severity in 
those with Tourette’s syndrome. Finally, particularly important in the context of the very large sample sizes 
required for the success of GWAS efforts, our results suggest that future genetic association studies may benefit 
from expanding disease definitions to include case subjects with both Tourette’s and chronic tics. 
Our genome-wide cell and tissue-based enrichment analyses implicate modulation of gene expression through 
noncoding variants as a fundamental mechanism in the pathogenesis of Tourette’s syndrome. All of the top 
tissues in the enrichment analyses were derived from brain, although dorsolateral prefrontal cortex 
(Brodmann’s area 9) was the only tissue in which eQTL enrichment surpassed Bonferroni correction. The five 
tissues with the strongest eQTL enrichment (frontal cortex, caudate, putamen, nucleus accumbens, and 
cerebellum) all represent key nodes within the cortico-striatal and cortico-cerebellar circuits that have been 
implicated in Tourette’s pathophysiology (1). These results support the hypothesis that Tourette’s syndrome is a 
developmental circuit disorder affecting motor, cognitive, and behavioral control (as manifested by tics and 
attention-deficit and obsessive-compulsive symptoms) and suggest that future GWAS analyses in larger data 
sets should aid in identifying not only the individual genes underlying susceptibility to Tourette’s syndrome but 
also core pathways in the development and regulation of these circuits that could serve as targets for 
modulation-based therapies. 
Limitations 
This study has several potential limitations, the most significant of which is the sample size. Although this is the 
largest Tourette’s syndrome GWAS conducted to date, our sample of fewer than 5,000 case subjects is clearly 
not yet sufficient to identify definitive Tourette’s susceptibility variants, as demonstrated by the failure of the 
top GWAS SNP to replicate in the deCODE sample. Additional potential limitations are also related to sample 
size, including reduced power to examine additional clinical variables of interest, such as age at onset of tics and 
co-occurring psychiatric illnesses such as obsessive-compulsive disorder and attention deficit hyperactivity 
disorder. However, we anticipate that most, if not all, of these limitations can be resolved by substantial 
increases in the number of Tourette’s syndrome case subjects collected for GWAS, an effort that is currently 
under way. 
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